Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. REVB
REVB logo

REVB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.990
1 Day change
-2.94%
52 Week Range
12.880
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

REVB is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows some short-term technical improvement, but there is no strong proprietary buy signal, no recent news catalyst, no supportive analyst momentum, and no financial data to justify a confident long-term entry. Based on the available data, the best direct call is to hold off rather than buy now.

Technical Analysis

REVB is trading at 1.08, right near its pivot level of 1.028 and just below resistance at 1.089. MACD histogram is positive and expanding, which suggests short-term bullish momentum, but RSI_6 at 64.56 is only moderately strong and not yet overbought. Moving averages are converging, which points to a developing but not decisive trend. Overall, the chart shows a mild bullish bias, but not a strong breakout setup. The next likely upside levels are 1.089 and 1.127, while support sits at 0.967 and 0.929.

Positive Catalysts

  • No news in the recent week. The only mildly positive factor is the improving MACD momentum and the stock trend estimate suggesting a possible short-term move higher. There is also no negative insider or hedge fund trend, which keeps sentiment neutral rather than bearish.

Neutral/Negative Catalysts

  • No recent news means there is no event-driven catalyst to support a stronger move. AI Stock Picker shows no signal, and SwingMax shows no recent signal. Hedge funds are neutral, insiders are neutral, and congress trading data is unavailable, so there is no strong external buying support. Financial snapshot data is missing, and there is no valuation data to support a long-term thesis.

Financial Performance

No usable latest-quarter financial snapshot was provided, so there is no confirmed revenue, earnings, or growth trend to evaluate. The latest quarter season cannot be identified from the available data. Because of that, there is insufficient financial evidence to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible trend in Wall Street sentiment. With no recent upgrades, downgrades, or target revisions, analyst view appears unavailable rather than supportive. Wall Street pros and cons cannot be meaningfully separated from the data, but the lack of positive analyst momentum is a negative for a long-term buy case.

Wall Street analysts forecast REVB stock price to rise
Analyst Rating
0
Wall Street analysts forecast REVB stock price to rise
Buy
Hold
Sell
0
Current: 1.020
sliders
Low
0
Averages
0
High
0
0
Current: 1.020
sliders
Low
0
Averages
0
High
0
Roth Capital
Jonathan Aschoff
Buy
maintain
$16
AI Analysis
2026-03-30
Reason
Roth Capital
Jonathan Aschoff
Price Target
$16
AI Analysis
2026-03-30
maintain
Buy
Reason
Roth Capital analyst Jonathan Aschoff says Revelation Biosciences showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokine levels, and restoring immunocompetence in chronic kidney disease patient peripheral blood mononuclear cells regardless of background inflammation levels. Gemini significantly reduced the number of elevated cytokines at all measured timepoints after a single dose out to seven days, the analyst tells investors in a research note. Roth says the results show Gemini's "broad effect." It keep a Buy rating on the shares with a $16 price target. The stock in late day trading is up 6% to $1.20.
Roth Capital
Buy
downgrade
$20 -> $16
2026-02-27
Reason
Roth Capital
Price Target
$20 -> $16
2026-02-27
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Revelation Biosciences to $16 from $20 but keeps a Buy rating on the shares. The company ended 2025 with pro forma cash of $17.3M, enough funding into Q1 of 2027, the analyst tells investors in a research note. The firm further cites the Gemini trial safety data, which was well-tolerated at the target dose with all adverse events reported as mild at that dose and including transient headache, chills, loose stool, and body aches.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for REVB
Unlock Now

People Also Watch